Canada Cell Therapy Manufacturing Market to be Dominated by the Allogenic Cell Therapy Segment through 2028
The Canada cell therapy manufacturing market is
expected to grow during the forecast period due to the increasing prevalence of
chronic diseases.
According to TechSci Research report, “Canada Cell
Therapy Manufacturing Market - By Region, Competition, Forecast and
Opportunities, 2018-2028”, the Canada cell therapy manufacturing market is
anticipated to grow at an impressive rate during the forecast period. This
can be ascribed to the emergence of advanced therapies that has played a key
role in transforming the treatment paradigm of several life-threatening and
rare diseases and in reshaping the biopharmaceutical industry across the
region. Similarly, rapid growth of the advanced therapy landscape is one of the
major factors propelling the growth of the Canada cell therapy manufacturing market.
Additionally, several companies have expanded their production capabilities for
vector production as well as undertaken various strategic initiatives to
produce investigational therapies. Such factors will escalate the growth of the
Canada cell therapy manufacturing market in the coming years. Besides,
increasing number of products entering the marketplace and the high number of
ongoing clinical trials will further support the growth of the Canada cell
therapy manufacturing market during the forecast period.
However, the development of new cell-based therapies
requires significant investment in research and development that can result in
lower image quality and accuracy, longer wait times for patients, and higher
maintenance costs, which can lead to a lack of competition and higher prices
for consumers. Similarly, the regulatory environment for cell therapy
manufacturing can be complex and time-consuming and companies must stay up to
date with the latest guidelines to ensure compliance which may hamper the
growth of the Canada cell therapy manufacturing market during the forecast
period. Also, the lack of standardized manufacturing processes for cell-based
therapies can pose a challenge for the industry. Manufacturing processes can
vary significantly from one product to another, which can further restrict the
growth of the Canada cell therapy manufacturing market during the forecast
period.
Browse over XX market data Figures spread through 70
Pages and an in-depth TOC on "Canada Cell Therapy Manufacturing Market.”
The Canada cell therapy manufacturing market can be
segmented by therapy, source of cell, source, application, end user, and
region. Based on source of cell, the Canada cell therapy manufacturing market
can be divided into autologous v/s allogenic. The allogenic segment dominated
the Canada cell therapy manufacturing market in 2022, and it is expected to
continue maintaining its dominance during the forecast period. This can be
ascribed to increasing inclination of physicians toward the therapeutic use of
allogeneic therapies and rising awareness about the use of cord cells and
tissues across various therapeutic areas. Similarly, growing to fund new cell
lines, increasing partnerships and acquisitions, and the development of
advanced genomics methods for cell analysis are the major factors influencing
the growth of the Canada cell therapy manufacturing market during the forecast
period.
Based on end users, the Canada cell therapy
manufacturing market can be segmented into pharmaceutical & biotechnology
companies, academic & research institutes, and others. The pharmaceutical
& biotechnology company segment is expected to dominate the Canada cell
therapy manufacturing market during the forecast period due to the rising
demand for advanced cell therapies for the treatment of chronic diseases.
Major companies operating in the Canada cell therapy
manufacturing market are:
- Novartis Pharmaceuticals Canada Inc.
- Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Thermo Fisher Scientific Inc.
- Catalent Ontario Ltd.
- Takeda Canada Inc.
- Amgen Canada Inc.
Download Free Sample Report
Customers can also request for 10%
free customization in this report.
“The Canada cell therapy manufacturing market is
expected to grow during the forecast period due to the presence of strong biotechnology
industry along with extensive research and development activities for cell
therapy manufacturing in research institutes within the region. Similarly, the
growing demand for personalized medicines and increasing government initiatives
to promote stem cell therapies among people and healthcare is expected to drive
the growth of the Canada cell therapy manufacturing market during the forecast
period. Also, increasing aging population, rising cases of chronic diseases,
and growing trend of preventive diagnostic practices will further propel the
growth of the Canada cell therapy manufacturing market during the forecast
period. Furthermore, increasing collaborations by market players is a major
factor influencing the growth of the Canada cell therapy manufacturing market.
Besides, recent trends of collaborations between local and global companies are
expected to create a lucrative growth of the Canada cell therapy manufacturing
market during the forecast period,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based global management consulting firm.
“Canada Cell Therapy Manufacturing Market – By Therapy
(T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, and Stem
Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Source
(In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular
Diseases, Orthopaedic Diseases, and Others), By End User (Pharmaceutical &
Biotechnology Companies, Academic & Research Institutes, and Others) and By
Region, Competition, Forecast & Opportunities, 2018-2028F” has
evaluated the future growth potential of the Canada cell therapy manufacturing
market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in the Canada cell therapy
manufacturing market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com